MannKind vs Xeris Biopharma
MNKD and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MNKD and XERS compare
Xeris Biopharma is the larger company, worth 2.3 times as much as MannKind ($3.0B against $1.3B).
Xeris Biopharma grew revenue faster over the last twelve months (38.4% versus 31.7% for MannKind).
Xeris Biopharma keeps more of each dollar of sales as profit, with a net margin of −1.8% compared with −18.1% at MannKind.
Xeris Biopharma scores higher on the StockData Score (11 against 6 for MannKind), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MNKD | XERS |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $3.0B |
| Share price | $4.13 | $16.66 |
| Change, 1 year | −21.3% | 119% |
| Change, 5 years | −13.1% | 634% |
| Beta (5Y) | 1.07 | 1.15 |
| Employees | 241 | 435 |
| StockData Score | ||
| Total score | 6 | 11 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.2× (better) | 8.2× |
| P/B | – | 62.3× |
| EV/EBITDA | 87.0× | 64.4× (better) |
| FCF yield | −5.9% | – |
| Fair value | $1.11 | $3.65 |
| Margin of safety | −273% (better) | −357% |
| Growth | ||
| Revenue growth (TTM) | 31.7% | 38.4% (better) |
| Revenue growth, 5Y average | 39.9% | 70.2% (better) |
| Net income growth (TTM) | −356% | – |
| EPS growth (TTM) | −330% | – |
| Profitability | ||
| Gross margin | 88.6% (better) | 87.4% |
| Operating margin | −2.9% | 12.7% (better) |
| Net margin | −18.1% | −1.8% (better) |
| FCF margin | −19.0% | – |
| Return on equity | – | −27.1% |
| Return on invested capital | – | 31.5% |
| Financial health | ||
| Debt / equity | – | 3.89 |
| Net debt / EBITDA | – | 1.22 |
| Interest coverage | −0.3× | 1.7× (better) |
| Current ratio | 2.22 (better) | 2.15 |
| Altman Z-score | −4.52 | 4.26 (better) |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 56.7% | 59.4% |
| Held by insiders | 2.5% | 5.2% |
| Insider net buying, 12 months | −$2.9M (better) | −$5.8M |
| Short interest, % of float | 8.4% | 5.2% |
Go deeper
- MNKD stock overview
- MNKD income statement
- MNKD valuation and score
- XERS stock overview
- XERS income statement
- XERS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.